Please find enclosed Investor presentation for quarter ended 30 September, 2026

27th October, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2026 Dear Sir / Madam, Further to our intimation made earlier with regard to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2026 (‘Financial Results’), please find enclosed herewith the Press Release and the Investor Presentation on the Financial Results. The above information is also available on the website of the Company at https://www.piramalpharma.com/ . You are requested to kindly take the above information on record. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl.: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com PRESS RELEASE Piramal Pharma Limited Announces Results for Q2 and H1 FY27 Mumbai, India | October 27, 2026: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Consolidated Financial Highlights (in ₹ Crores or as stated) YoY YoY Particulars Q2FY27 Q2FY26 H1FY27 H1FY26 Growth Growth Revenue from Operations 2,617 2,044 28% 4,887 3,977 23% CDMO 1,424 1,044 36% 2,611 2,041 28% CHG 849 644 32% 1,592 1,281 24% PCH 359 319 13% 706 621 14% EBITDA 385 224 72% 669 389 72% EBITDA Margin 14.7% 11.0% 13.7% 9.8% PAT 5 (99) 105% (64) (181) 64% Key Highlights • Broad-based Revenue Growth: Revenue grew 28% YoY in Q2FY27 and 23% YoY in H1FY27, driven by strong performance across all three businesses. • Significant Profitability Improvement: EBITDA increased 72% YoY in Q2FY27 and H1FY27, with over 350bps EBITDA margin expansion in both periods. This was driven by higher capacity utilization, operating leverage, disciplined execution, and sustained cost optimization initiatives. • Robust RFP Activity and Order Inflows: Added 22 new customers and successfully hosted 110 customer audits in H1FY27. • Best-in-Class Quality & Compliance: Successfully completed 12 regulatory inspections and 110 customer audits during H1FY27, while maintaining the Company’s track record of no Official Action Indicated classifications across US FDA inspections. • Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, we upgrade our FY27 outlook and now expect revenue growth of 19% to 20%, accompanied by meaningfully higher profitability. Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across our businesses, disciplined execution, and improved operating leverage. The performance was led by our CDMO business, which grew 28% on the back of strong order inflows and robust execution. Our CHG business complemented this momentum with 24% growth, supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, we are well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline.” Page 1 of 4 Key Business Highlights Contract Development and Manufacturing Organization (CDMO): - Robust Growth: Broad-based growth across India and overseas sites, supported by healthy commercial demand, improved execution and disciplined cost management. India and North America led performance across the network. - Enhanced Profitability: Better capacity utilization and operating leverage drove a meaningful improvement in profitability. - Strong Commercial Momentum: Strong RFP activity and order inflows resulted in addition of 22 new customers during H1FY27. Phase III pipeline increased to 28 molecules from 25 as of March 2026. - Innovation and On-Patent Revenue Growth: Innovation-related revenues grew 24%, while on- patent commercial manufacturing revenues grew 39% in H1FY27. - Differentiated Capabilities: Strengthened biologics capabilities through acquisition of a controlling stake in Yapan Bio. The Lexington expansion remains on track, will add sterile fill-finish capabilities, completing the integrated ADC offering. Commissioned a new microbiology laboratory at the site. - ADC Services continued to gain momentum, with revenues up 51% YoY in H1FY27. - Deepening Customer Engagement: Successfully hosted 110 customer audits during H1FY27, reflecting continued customer engagement and confidence in the Company’s quality systems. Complex Hospital Generics (CHG): - Inhalation Anesthesia Leadership: Maintained leadership in the US Sevoflurane market with a 48% value share, while building traction in ex-US markets. (Source: IQVIA) - Kenalog® Integration: Kenalog® contributed to CHG revenue during Q2FY27 and is expected to be an important growth driver for the business in FY27. - Intrathecal Therapy: Maintained the #1 position in the US Intrathecal Baclofen market. (Source: IQVIA) - Injectable Pain Management: Continued collaboration with suppliers to ensure product availability. - Building a Differentiated and Specialty Portfolio: Continued investments in 505(b)(2) products, complex and differentiated generics, branded products, in-licensing and co-development to strengthen the long-term portfolio. Piramal Consumer Healthcare (PCH): - Power Brands Continue to Outperform: Power Brands grew 21% YoY in H1FY27, contributing 53% of PCH sales, reflecting the strength of the core portfolio. - Strong E-commerce Momentum: Grew 32% YoY in H1FY27 and contributed 28% of PCH sales. - Innovation and Premiumization: Continued focus on fewer, larger, and higher-potential launches to enhance portfolio quality and margins. Launched the 'Vizible' range under Lacto Calamine to strengthen presence in premium skincare. - Sustained Brand Investments: Invested approximately 11% of PCH sales in media and trade promotion across digital and traditional channels to support long-term brand growth. - Bayer Distribution Agreement: The distribution agreement will naturally expire in December 2026. The transition is being jointly managed to ensure business continuity, with no material impact expected on FY27 guidance. Page 2 of 4 Consolidated Profit and Loss Statement (in ₹ Crores or as stated) Quarterly Half Yearly Particulars YoY QoQ YoY Q2FY27 Q2FY26 Q1FY26 H1FY27 H1FY26 Change Change Change Revenue from Operations 2,617 2,044 28% 2,270 15% 4,887 3,977 23% Other Income 36 66 -45% 89 (60)% 125 124 1% Total Income 2,653 2,109 26% 2,359 12% 5,012 4,101 22% Material Cost 906 703 29% 852 6% 1,758 1,397 26% Employee Expenses 714 611 17% 676 6% 1,390 1,230 13% Other Expenses 648 571 13% 547 18% 1,195 1,085 10% EBITDA 385 224 72% 285 35% 669 389 72% Interest Expenses 88 82 6% 88 (1)% 176 169 4% Depreciation 233 203 15% 224 4% 457 400 14% Share of Net Profit of Associates 18 15 20% 20 (9)% 37 33 12% Profit Before Tax 82 (46) 277% (7) 1,194% 74 (146) 151% Tax 77 53 44% 62 24% 139 56 149% Net Profit after Tax 5 (99) 105% (69) 107% (64) (202) 68% Exceptional item1 - - NA - NA - 21 NA Net Profit after Tax after 5 (99) 105% (69) 107% (64) (181) 64% Exceptional Item 1. Exceptional items include, one time insolvenc [Showing first 8,000 characters — download PDF for full document]